首页> 外文期刊>Chinese Jouranl of Integrative Medicine >A Clinical Study of Yigu Capsule in Treating Postmenopausal Osteoporosis
【24h】

A Clinical Study of Yigu Capsule in Treating Postmenopausal Osteoporosis

机译:益骨胶囊治疗绝经后骨质疏松症的临床研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To observe the efficacy and safety of Yigu capsule (YGC), a Chinese herbal compound preparation, in treating postmenopausal osteoporosis (PMO) and to explore its possible mechanism. Methods: The clinical study was conducted in a prospective, randomized, double blinded method lasting for 6 months with placebo and positive control. Two hundred and ten PMO patients with confirmed diagnosis were assigned into the YGC group, the calciferol group and the placebo group. Besides being administered element calcium, they were treated with YGC, calciferol capsule and placebo capsule respectively. And such symptoms as newly found fracture and ostealgia, bone mineral density (BMD) of the 2nd - 4th lumbar vertebrae (L_(2-4)) and upper femur, blood and urinary indexes for bone metabolism, sex hormone level and adverse reaction that occurred in patients were observed. Results: In the YGC group, the total effective rate was 95.50%, with no new occurrence of fractures, which was significantly better than that in the other two groups (P < 0.05). Moreover, in the YGC group, the increase rate of BMD was 9.83% in L_(2-4), 4.09% in femoral neck, 4.60% in Wards triangle, 3.00% in greater trochanter, which was also better than that in the placebo group ( P < 0.05, P < 0.01). As compared with the placebo group, levels in the YGC group of u-rinary oxyproline hydroxyproline/creatinine, urinary calcium/creatinine were significantly lower, serum and bone alkaline phosphatase, osteocalcin, estradiol and estradiol/testosterone were significantly higher, but no difference was shown in the comparison of testosterone level. In the observation period, no abnormality in blood or urine routine, liver or renal function was found. Only mild, transient gastro-intestinal response occurred in individual patients, but it did not affect the treatment. Conclusion: YGC could treat PMO effectively, as it could obviously increase the BMD of lumbar vertebrae and coxafemoral bone, elevate the alleviating rate of ostealgia and incessant motion time, yet causing no newly found compressive fracture of vertebrae, or and any related adverse reaction. YGC could not only promote the formation, but also inhibit the absorption of bone as well as increase the sex hormone level. Therefore, it is a pure Chinese herbal compound preparation worthy of further research and development.
机译:目的:观察中药复方益骨胶囊(YGC)治疗绝经后骨质疏松症(PMO)的有效性和安全性,并探讨其可能的作用机制。方法:本研究以前瞻性,随机,双盲方法进行,为期6个月,接受安慰剂和阳性对照。将确定诊断的PMO患者210例分为YGC组,钙化甾醇组和安慰剂组。除给予元素钙外,还分别用YGC,钙化醇胶囊和安慰剂胶囊治疗。新出现的骨折和骨痛,第二至第四腰椎骨密度(L_(2-4))和上股骨,血液和尿液指标,骨代谢,性激素水平和不良反应等症状观察患者发生情况。结果:YGC组总有效率95.50%,无新发骨折发生,明显优于其他两组(P <0.05)。此外,在YGC组中,L_(2-4)的BMD增加率为9.83%,股骨颈为4.09%,Wards三角形为4.60%,大转子为3.00%,也好于安慰剂组(P <0.05,P <0.01)。与安慰剂组相比,YGC组的尿中羟脯氨酸羟脯氨酸/肌酐,尿钙/肌酐水平明显降低,血清和骨碱性磷酸酶,骨钙素,雌二醇和雌二醇/睾丸激素水平明显升高,但无差异显示在比较睾丸激素水平。在观察期内,未发现血液或尿常规,肝或肾功能异常。个别患者仅发生轻度,短暂的胃肠道反应,但并未影响治疗。结论:YGC可以有效治疗PMO,因为它可以明显增加腰椎和髋臼骨的骨密度,提高骨痛的缓解率和持续的运动时间,但不会引起新发现的椎体压缩性骨折或任何相关的不良反应。 YGC不仅可以促进骨骼形成,而且可以抑制骨骼吸收并增加性激素水平。因此,它是一种值得进一步研究开发的纯中草药复方制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号